조지아의 다발성 골수종 임상 시험
다발성 골수종 관련 연구 49개가 조지아 내 여러 지역에서 참여자를 모집하고 있습니다.
조지아의 도시
공식 연구 텍스트(영어)
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- City Of Hope - Atlanta /ID# 280294, Newnan
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Atlanta
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Emory University Winship Cancer Center, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT04973605A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University, Atlanta
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07518186A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07073547A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Winship Cancer Institute Emory University, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06768489A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University, Atlanta
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University Winship Cancer Institute, Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT04634552A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Emory University - Winship Cancer Institute, Atlanta
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07393282A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- City of Hope Cancer Center, Newnan
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Emory University, Atlanta
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05201781A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University Hospital, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT07116616A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Winship Cancer Institute of Emory University /ID# 277667, Atlanta
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion, Savannah
- 외 3개
피험자 모집 중2상
12세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT02693535Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Winship Cancer Institute of Emory University, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT04879043Collection of Tissue Samples for Cancer Research
- Emory University, Atlanta
피험자 모집 중관찰 연구
2 Months · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT00900198A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Winship Cancer Institute, Emory University, Atlanta
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Winship Cancer Institute of Emory University, Atlanta
- Northside Hospital, Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT06297226Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Emory University Hospital Midtown, Atlanta
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT07555938Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
- Emory University/Winship Cancer Institute, Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT05208307A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Emory University Hospital, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 28. 업데이트됨 · NCT07075185A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 27. 업데이트됨 · NCT07681596A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Macon
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT07227311AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT06106945A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- The Winship Cancer Institute of Emory University, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Atlanta
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 14. 업데이트됨 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Winship Cancer Institute, Emory University, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 12. 업데이트됨 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Winship Cancer Institute, Emory University, Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT07284758Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
- Emory University Hospital/Winship Cancer Institute, Atlanta
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 7. 23. 업데이트됨 · NCT07101445A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Winship Cancer Institute of Emory University /ID# 274830, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 7. 21. 업데이트됨 · NCT06892522A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Northside Hospital, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 16. 업데이트됨 · NCT06121843A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Winship Cancer Institute of Emory University, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 8. 업데이트됨 · NCT05137054Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Emory Winship Cancer Institute, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 24. 업데이트됨 · NCT04068597Personalized Autologous Transplant for Multiple Myeloma
- Winship Cancer Institute of Emory University, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 15. 업데이트됨 · NCT04483206Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- Emory University Hospital/Winship Cancer Institute, Atlanta
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 6. 5. 업데이트됨 · NCT03858205Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Emory University Hospital, Atlanta
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT05243797Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Emory Winchip Cancer Center, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 5. 19. 업데이트됨 · NCT06433947A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Atlanta
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 4. 22. 업데이트됨 · NCT06679101CAR T-cell Therapy in Patients With Renal Dysfunction
- Caitlin Guzowski, Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 20. 업데이트됨 · NCT05909059ClinicalTrials.gov 출처, 2026. 10. 3. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.